zeaxanthin
Phase 1Small molecule
zeaxanthin is one of 21 small molecule programs targeting Macular Telangiectasia Type 2. It is currently in Phase 1.
2
Indications
2
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
31 competitors in Metastatic Cancer
#DrugCompanyPhaseTrials
1Avastin
RocheApproved
Keytruda
Merck & Co.Phase 2
Opdivo
Bristol-Myers SquibbPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Proleukin
IIovance Biotherapeutics, Inc.
Phase 2
Yervoy
Bristol-Myers SquibbPhase 2
Lenvima
EisaiPhase 2
Talzenna
PfizerPhase 2
Zejula
GGlaxo Dba Glaxosmithkline
Phase 2
Jemperli
GGlaxo Dba Glaxosmithkline
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Macular Telangiectasia Type 21 trial
Metastatic Cancer1 trial
Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer
Recruiting·—·Phase 1·NCT05232409·72 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for zeaxanthin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- PPaul S. Bernstein